Our work suggests that regulation of inflammatory cytokines may be a new avenue of focus to enhance or diminish PD-L1 mediated T cell inhibition, especially when considering checkpoint therapy in individuals with HLA types associated with higher risk of developing autoimmunity or individuals that test positive for islet specific autoantibodies. Here, CD274 is linked to Autoimmunity.